Klára Prajzlerová

Klára Prajzlerová

Auto-generated profile, based on publicly available information

Klára Prajzlerová

Institute of Rheumatology, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Cytokine
Verified
Journal Article
Closed access
MFMária Filková
Mária Filková
ZVZdenka Vernerová
Zdenka Vernerová
HHHana Hulejová
Hana Hulejová
KPKlára Prajzlerová
Klára Prajzlerová
DVDavid Veigl
David Veigl
LŠLadislav Šenolt
Ladislav Šenolt

2 June 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
VHVeronika Hruskova
Veronika Hruskova
RJRomana Jandova
Romana Jandova
LVLucia Vernerova
Lucia Vernerova
HMHerman Mann
Herman Mann
OPOndrej Pecha
Ondrej Pecha
LŠLadislav Šenolt
Ladislav Šenolt
MicroRNAs (miRNAs) are small RNAs that regulate gene expression by targeting mRNA. It was proved that some miRNAs are significantly deregulated in rheumatoid arthritis (RA). MicroRNA-125b negatively regulates expression of TNF-α, which plays a crucial role in RA pathogenesis. The aim of this study was to determine the treatment outcome of patients with early RA based on the expression of circulating and cellular miR-125b. Total RNA was isolated from the plasma and peripheral blood mononuclear cells (PBMCs) of 58 patients with early RA before and three months after treatment initiation and of 54 age- and sex-matched healthy controls (HC). The expression of miR-125b was measured by TaqMan quantitative PCR. The treatment responders were defined as patients achieving remission or low disease activity (28-joint count disease activity score (DAS28) <3.2). Receiver operating characteristic (ROC) curve and stepwise backward multivariable logistic regression analyses of miR-125b expression were used to predict the disease outcome at three and six months after initiation of treatment. The expression of miR-125b in the PBMCs and plasma of treatment-naïve early RA patients was significantly lower than that of HC and increased significantly after three months of treatment, particularly in responders. However, only the cellular expression of miR-125b was inversely correlated with disease activity. MiR-125b expression in PBMCs was higher in responders than in non-responders after three months (p = 0.042). Using ROC analysis, the cellular expression of miR-125b, but not the disease activity at baseline, predicted the treatment response after three months of therapy (area under the curve 0.652 (95 % CI 0.510 to 0.793); p = 0.048). The expression of miR-125b in PBMCs of treatment-naïve patients may present a novel biomarker for monitoring the treatment outcome during the early phase of RA.

1 June 2016 in Autoimmunity Reviews
Verified
Journal Article
Closed access
KPKlára Prajzlerová
Klára Prajzlerová
KBKristýna Bubová
Kristýna Bubová
Karel PavelkaKarel Pavelka
Karel Pavelka
LŠLadislav Šenolt
Ladislav Šenolt
MFMária Filková
Mária Filková

26 April 2017 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
LCLucie Andrés Cerezo
Lucie Andrés Cerezo
BŠBarbora Šumová
Barbora Šumová
KPKlára Prajzlerová
Klára Prajzlerová
DVDavid Veigl
David Veigl
DDDres Damgaard
Dres Damgaard
LŠLadislav Šenolt
Ladislav Šenolt
Calgizzarin (S100A11) is a member of the S100 protein family that acts in different tumors by regulating a number of biologic functions. Recent data suggest its association with low-grade inflammation in osteoarthritis (OA). The aim of our study is to compare S100A11 expression in the synovial tissues, synovial fluid and serum of patients with rheumatoid arthritis (RA) and osteoarthritis (OA) and to characterize the potential association between S100A11 and disease activity. S100A11 protein expression was detected in synovial tissue from patients with RA (n = 6) and patients with OA (n = 6) by immunohistochemistry and immunofluorescence. Serum and synovial fluid S100A11 levels were measured by ELISA in patients with RA (n = 40) and patients with OA (n = 34). Disease activity scores in 28 joints based on C-reactive protein (DAS28-CRP) were used to assess disease activity. Cytokine content in peripheral blood mononuclear cells (PBMCs), synovial fibroblasts (SFs) and synovial fluid was analysed by ELISA, western blotting or cytometric bead array. S100A11 expression was significantly up-regulated in the synovial lining and sublining layers (p < 0.01) and vessels (p < 0.05) of patients with RA compared to patients with OA, and was associated with fibroblasts and T cells. S100A11 was significantly increased in synovial fluid (p < 0.0001) but not in serum (p = 0.158) from patients with RA compared to patients with OA when adjusted for age and sex. Synovial fluid S100A11 correlated with DAS28 (r = 0.350, p = 0.027), serum CRP (r = 0.463, p = 0.003), synovial fluid leukocyte count (r = 0.677, p < 0.001), anti-cyclic citrullinated peptide antibodies (anti-CCP) (r = 0.424, p = 0.006) and IL-6 (r = 0.578, p = 0.002) and IL-8 (r = 0.740, p < 0.001) in synovial fluid from patients with RA. PBMCs and SFs isolated from patients with RA synthesized and spontaneously secreted higher levels of S100A11 in comparison with PBMCs and SFs from patients with OA (p = 0.011 and 0.03, respectively). S100A11 stimulated the production of the pro-inflammatory cytokine IL-6 by PBMCs (p < 0.05) and SFs (p < 0.01). Our data provide the first evidence of S100A11 up-regulation and its association with inflammation and disease activity in patients with RA.

22 September 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KPKlára Prajzlerová
Klára Prajzlerová
KBKristýna Bubová
Kristýna Bubová
MHMarketa Husakova
Marketa Husakova
ŠFŠárka Forejtová
Šárka Forejtová
AJAstrid Jüngel
Astrid Jüngel
MFMária Filková
Mária Filková
Dysregulation of miRNAs and their target genes contributes to the pathophysiology of autoimmune diseases. Circulating miRNAs may serve as diagnostic/prognostic biomarkers. We aimed to investigate the association between circulating miRNAs, disease activity and spinal involvement in patients with axial spondyloarthritis (AxSpA). Total RNA was isolated from the plasma of patients with non-radiographic (nr)AxSpA, patients with ankylosing spondylitis (AS) and healthy controls (HC) via phenol-chloroform extraction. A total of 760 miRNAs were analysed with TaqMan® Low Density Arrays, and the expression of 21 miRNAs was assessed using single assays. Comprehensive analysis demonstrated the differential expression of miRNAs among patients with progressive spinal disease. Of the 21 miRNAs selected according to their expression patterns, the levels of miR-625-3p were significantly different between nr-AxSpA patients and HCs. We found no correlation between miRNA levels and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in nr-AxSpA patients. Selected miRNAs, such as miR-29a-3p, miR-146a-5p or miR-222-3p with an established role in extracellular matrix formation and inflammation were associated with spinal changes and/or disease activity assessed by BASDAI in AS patients, including miR-625-3p reflecting disease activity in AS with spinal involvement. Our data indicate that circulating miRNAs play a role in the pathogenesis of AxSpA and are also suggestive of their potential as biomarkers of disease progression. We hypothesize that differential systemic levels of miRNA expression reflect miRNA dysregulation at sites of spinal inflammation or bone formation where these molecules contribute to the development of pathophysiological features typical of AxSpA.

1 March 2009 in High Pressure Research
Verified
Journal Article
Closed access
MBMilos Beran
Milos Beran
RKRadek Klubal
Radek Klubal
PMPetr Molik
Petr Molik
JSJan Strohalm
Jan Strohalm
MUMarian Urban
Marian Urban
KPKlara Prajzlerova
Klara Prajzlerova
This work describes the effect of isostatic pressure 500 MPa on tryptic and chymotryptic hydrolysis of α- and β-casein, bovine serum albumin (BSA), β-lactoglobulin (β-Lg) and α -lactalbumin (α-La). Digestion was also conducted at atmospheric pressure. The extent of hydrolysis and peptide profiles were analysed by gel-permeation and reverse-phase high-performance liquid chromatographies. The residual immunochemical reactivities of the protein hydrolysates were assessed by the Streptavidin ImmunoCAP system (Phadia) for determination of specific immunoglobulin type E (IgE) antibodies. We have found very significant changes of the peptide profiles and a progressive reduction in residual-intact proteins after applying high pressure during tryptic proteolysis of β-Lg and BSA and chymotryptic proteolysis of β-Lg, α-La and BSA. A statistically significant decrease of the residual immunochemical reactivities of β-Lg tryptic and α-La chymotryptic hydrolysates prepared under high pressure, in comparison with the control samples hydrolysed at atmospheric pressure, was also observed.